US Patent 6,210,705: Scope, Claim Construction, Expiration, and Methylphenidate Transdermal Patent Landscape

US Patent 6,210,705 protects a methylphenidate transdermal or transmucosal delivery system that uses a flexible, finite dosage form, delivers methylphenidate for at least 10 hours, and limits acid-functional monomers in the adhesive or polymer matrix. The patent covers both compositions and methods for treating attention deficit disorder and attention-deficit/hyperactivity disorder.

The patent’s expected 20-year term ran from its earliest nonprovisional filing date and expired on December 22, 2018. It therefore does not provide an enforceable patent barrier against current generic development. Its technical disclosure remains relevant to freedom-to-operate analyses involving methylphenidate patches, adhesive selection, drug loading, delivery duration, and formulation design.

What does US Patent 6,210,705 protect?

The patent protects a transdermal methylphenidate system with five central limitations:

Methylphenidate is incorporated into a flexible, finite system.
The system is applied topically to skin or mucosa.
The formulation delivers methylphenidate at substantially zero-order kinetics.
Delivery continues for at least 10 hours, with dependent claims covering approximately 12 to 20 hours and 14 to 16 hours.
Acid-functional monomers comprise no more than about 5 wt%, with narrower claims limiting them to no more than about 1 wt%.

The patent is directed primarily to a drug-in-adhesive or related patch architecture rather than an oral dosage form, injectable product, or conventional topical cream.

Patent identification and basic data

Item	Data
Patent	US 6,210,705
Title	Methylphenidate transdermal delivery system
Patent type	Utility patent
Technology	Transdermal and transmucosal methylphenidate delivery
Priority framework	Earliest priority commonly identified as December 22, 1997
Filing date	December 22, 1998
Issue date	April 3, 2001
Expected expiration	December 22, 2018
Primary therapeutic area	ADHD and attention deficit disorder
Dosage form	Flexible, finite topical delivery system
Key formulation constraint	No more than about 5 wt% acid-functional monomers
Narrower formulation constraint	No more than about 1 wt% acid-functional monomers
Commercial product association	Daytrana methylphenidate transdermal system

The statutory term is calculated under the patent-term rules applicable to the filing history. The patent expired before the current generic competition period for methylphenidate transdermal systems.

How are the claims organized?

Claims 1 through 15 are composition claims. Claims 16 and 17 are treatment-method claims based on the long-duration delivery formulation. Claims 18 through 24 are composition claims directed to a 24-hour delivered dose. Claims 25 and 26 are corresponding treatment-method claims.

Claim architecture

Claim group	Subject matter	Principal limitations
1	Broad composition claim	Topical methylphenidate, flexible finite system, at least 10-hour delivery, substantially zero-order kinetics, no more than 5 wt% acid-functional monomers
2-5	Drug identity and loading	Methylphenidate base, at least 26.4 mg per approximately 10 cm², base/basic salt combination or ester, substantially d-threo enantiomer
6-12	Adhesive systems	Adhesive selected from acrylics, rubbers, bioadhesives, polysiloxanes, polyacrylates, polyvinylpyrrolidones, vinylpyrrolidone copolymers, styrene block polymers, and mixtures
13-15	Duration and acid-functional content	Approximately 12-20 hours, approximately 14-16 hours, and no more than 1 wt% acid-functional monomers
16-17	Treatment method	Topical administration for ADD or ADHD using the claim 1 system
18-24	24-hour composition	0.5-100 mg total delivered methylphenidate over 24 hours; 2.5-20 mg per 24 hours; specified weight-based dosing
25-26	24-hour treatment method	Topical administration using the claim 18 formulation

What is the broadest independent claim?

Claim 1 is the principal composition claim. It requires a formulation containing methylphenidate in a flexible, finite system and imposes both performance and composition limitations.

A product would need to satisfy all of the following to fall within the literal scope of claim 1:

It contains methylphenidate.
The methylphenidate is in a flexible, finite system.
The system is intended for delivery to skin or mucosa.
The amount is therapeutically effective.
Delivery produces substantially zero-order kinetics.
Delivery continues for at least 10 hours.
Acid-functional monomers comprise no more than about 5 wt%.

The claim does not require a specific adhesive chemistry. Claims 6 through 12 narrow the adhesive component but are not necessary to establish infringement of claim 1 if the independent claim’s other limitations are met.

The phrase “substantially zero order kinetics” is a significant scope limitation. It requires a relatively controlled delivery rate over the claimed interval. A patch that produces a pronounced initial burst, rapidly declining flux, or irregular delivery profile could challenge this limitation. The term would ordinarily be evaluated through formulation data, in vitro permeation testing, pharmacokinetic data, and the patent specification’s disclosure of acceptable variation.

What formulations are protected by US 6,210,705?

The claims cover multiple classes of adhesive and polymeric components.

Adhesive categories

Claim 7 lists:

Acrylic adhesives
Natural and synthetic rubbers
Bioadhesives
Polysiloxanes
Polyacrylates
Polyvinylpyrrolidones
Vinylpyrrolidone copolymers
Styrene block polymers
Mixtures of these materials

Dependent claims narrow those categories:

Claim 8 covers bioadhesives based on natural or synthetic polysaccharides and polyacrylic acid polymers.
Claim 9 identifies natural gums as a subset of natural polysaccharides.
Claim 10 covers capped or amine-compatible polysiloxane polymers.
Claim 11 covers nonfunctional or minimally functional acrylic polymers.
Claim 12 covers non-vinyl-acetate-containing polyacrylates.

The acid-functional monomer limitation is central because it limits the formulation’s ability to use carboxyl-containing or other acidic monomer functionality. In a patch, acid groups can affect methylphenidate partitioning, ionization, adhesive compatibility, skin permeation, crystallization, and drug release.

Methylphenidate forms

The claims cover several chemical forms:

Methylphenidate generally under claim 1.
Methylphenidate base under claim 2.
Methylphenidate base loaded at least 26.4 mg per approximately 10 cm² under claim 3.
A base/basic salt combination or ester under claim 4.
A composition substantially comprising the d-threo-methylphenidate enantiomer under claim 5.

Claim 5 is commercially important because d-threo-methylphenidate is the pharmacologically relevant enantiomer associated with conventional therapeutic methylphenidate products. The claim is not limited to a particular adhesive, patch size, backing layer, release liner, or manufacturing process.

How does the 24-hour claim set differ from the 10-hour claim set?

Claims 18 through 26 introduce a different dosing framework. Instead of focusing principally on the delivery interval and zero-order kinetics, these claims focus on the total amount delivered over 24 hours.

Key 24-hour limitations

The independent composition claim requires:

A flexible, finite methylphenidate system.
A total delivered amount of approximately 0.5 mg to 100 mg over 24 hours.
No more than about 5 wt% acid-functional monomers.

Claim 19 narrows the delivery rate to approximately 2.5 mg to 20 mg per 24 hours. Claims 20 through 23 specify daily weight-based dosing ranges:

Claim	Dose range
20	0.05-1.0 mg/kg/day
21	0.075-0.3 mg/kg/day
22	0.05-1.0 mg/kg/day
23	0.075-0.3 mg/kg/day

Claims 24 and 26 reduce the acid-functional monomer limit from about 5 wt% to about 1 wt%.

The 24-hour claims may be relevant to products that are worn for less than 24 hours but are characterized by a total daily delivered dose. A product’s label dosing instructions, actual delivery profile, patch area, drug loading, and residual drug content would be material to infringement analysis.

What is the significance of the acid-functional monomer limitation?

The acid-functional monomer limitation is the patent’s principal formulation-specific boundary.

At the broad level, the claims require no more than approximately 5 wt% acid-functional monomers. Narrower claims require no more than approximately 1 wt%. The calculation would depend on the claim construction and the formulation’s composition basis, including whether the percentage is measured against the adhesive polymer, the adhesive layer, or the overall system.

This limitation creates potential design-around routes, including:

Use of nonfunctional or minimally functional acrylic adhesives.
Use of silicone adhesives with compatible end groups.
Use of rubber-based pressure-sensitive adhesives.
Use of neutral polyacrylates.
Use of alternative drug-in-adhesive matrices.
Use of a reservoir or multilayer design in which methylphenidate is not incorporated into the same polymer environment.

A formulation using more than 5 wt% acid-functional monomers may avoid literal infringement of the independent claims, but equivalence issues could still depend on the patent’s prosecution history and the role of the acid functionality in controlling release.

When did US Patent 6,210,705 lose exclusivity?

US 6,210,705 expired on December 22, 2018, based on the patent’s 20-year term framework. The patent is therefore no longer an enforceable exclusionary right.

The expiration has several consequences:

A generic manufacturer no longer needs to establish noninfringement or invalidity of this patent for a post-expiration launch.
A Paragraph IV challenge directed solely to this patent no longer creates a meaningful delayed-entry risk.
A patent-term extension would have been required to extend the term beyond the ordinary expiration date.
Any six-month pediatric exclusivity period would have been tied to an otherwise relevant unexpired patent or exclusivity framework and would not restore the patent after its term ended.

Patent expiration does not eliminate regulatory requirements, trade-secret protection, or separately issued patents covering manufacturing methods, device components, packaging, or later formulations.

What is the Orange Book status of methylphenidate transdermal products?

Daytrana was approved by the FDA in 2006 under NDA 021514 as a methylphenidate transdermal system for ADHD. The FDA’s Orange Book has historically been the principal source for listed patents and exclusivity information for approved small-molecule products. [FDA, 2024a]

US 6,210,705 was associated with the transdermal methylphenidate product patent estate. Because the patent expired in 2018, it no longer presents an active Orange Book patent barrier. The relevant current question is whether later patents, if any, remain listed for a particular approved product and whether those patents cover the marketed formulation, delivery system, or method of use.

Orange Book analysis should distinguish among:

Expired formulation patents.
Unexpired later-issued patents.
Method-of-use patents.
Device or packaging patents.
Regulatory exclusivity.
Patents listed for a specific NDA rather than for methylphenidate products generally.

A patent that is absent from the current Orange Book may still be relevant in a non-Orange-Book patent dispute, but it would not necessarily trigger the same Hatch-Waxman notice and stay consequences.

Which companies have challenged or competed with Daytrana?

Competition has involved the product sponsor, transdermal drug-delivery companies, and generic manufacturers pursuing abbreviated applications. The relevant commercial product is Daytrana, originally developed by Noven Pharmaceuticals and commercialized through Shire-related entities.

The patent landscape is not limited to US 6,210,705. Generic-entry analysis should include:

Continuation and divisional patents from the same transdermal methylphenidate disclosure.
Later patents covering patch construction or adhesive chemistry.
Patents directed to wear time, skin adhesion, drug crystallization, or release control.
FDA-approved generic methylphenidate transdermal systems.
Authorized-generic arrangements and supply agreements.
Any litigation involving abbreviated applications.

Because US 6,210,705 expired, current competition depends primarily on other patent rights, regulatory approval, manufacturing capability, and commercial supply rather than this patent alone.

What patent litigation affects US 6,210,705?

The patent was part of the intellectual-property estate associated with methylphenidate transdermal products. Any historical Paragraph IV litigation would have involved questions such as:

Whether a proposed generic patch used a flexible finite system.
Whether its methylphenidate delivery profile was substantially zero-order.
Whether delivery lasted at least 10 hours.
Whether the adhesive contained more than the claimed amount of acid-functional monomers.
Whether the patent claims were invalid for anticipation or obviousness.
Whether the generic product infringed dependent claims covering methylphenidate form, drug loading, or adhesive chemistry.

The expiration of the patent removes the continuing injunction or launch-delay value of those claims. Historical litigation remains relevant for claim construction and design-around analysis, but it does not create a current exclusionary right.

How strong is the patent estate for methylphenidate patches?

The strength of US 6,210,705 was greatest when the patent was unexpired and when competing products used the same basic architecture: methylphenidate incorporated into a flexible adhesive patch with extended delivery.

Strength factors

Factor	Assessment
Core product coverage	Broad within the claimed patch architecture
Chemical scope	Broad enough to cover methylphenidate base, combinations, salts, esters, and d-threo material
Adhesive scope	Broad list of conventional adhesive classes
Performance limitation	Potentially difficult to prove because zero-order kinetics and duration require testing
Formulation limitation	The 5 wt% and 1 wt% acid-functional thresholds create measurable boundaries
Method claims	Cover treatment of ADD and ADHD, but are limited to the claimed delivery system
Current enforceability	None after expiration
Biosimilar relevance	None; methylphenidate is a small molecule
Design-around potential	Material, particularly through adhesive chemistry and delivery architecture

The patent was commercially meaningful because it combined product identity, delivery performance, and formulation composition in one claim set. Its present value is primarily historical and technical.

What generic launch risks exist after expiration?

The principal launch risks are no longer based on US 6,210,705 itself. They arise from other rights and operational barriers.

Potential current barriers

Later patents. Later patents may cover specific patch structures, adhesives, manufacturing methods, or approved uses.
Regulatory approval. An ANDA applicant must demonstrate pharmaceutical equivalence, bioequivalence, quality, and manufacturing compliance.
Transdermal bioequivalence. Demonstrating equivalence for a patch can require complex pharmacokinetic and adhesion data.
Manufacturing scale-up. Uniform drug loading, coating, drying, lamination, and package stability can create technical barriers.
Skin adhesion and irritation. Product performance depends on wear time, adhesion, residual drug, and skin tolerability.
Commercial supply. Controlled-substance handling and patch manufacturing capacity can restrict entry.
Trade secrets. Manufacturing parameters and adhesive-processing conditions may remain protected even after patent expiration.

An applicant using a materially different adhesive or delivery mechanism may avoid the expired claim set while still needing to address any later patent estate.

What manufacturing and IP barriers remain?

The patent claims identify several technical areas that can remain difficult to reproduce:

Maintaining consistent methylphenidate flux over the wear period.
Preventing crystallization of methylphenidate in the adhesive.
Controlling drug loading at or above the claimed amount.
Achieving adequate skin adhesion without excessive irritation.
Managing the interaction between methylphenidate ionization and adhesive functionality.
Producing a uniform coating over a commercial patch area.
Preserving stability during storage.
Maintaining acceptable delivery after exposure to heat, humidity, and mechanical stress.

These barriers are separate from patent enforceability. A manufacturer can avoid an expired patent yet still face substantial development and regulatory costs.

How does this patent compare with oral methylphenidate patents?

US 6,210,705 differs materially from patents covering oral methylphenidate products such as immediate-release tablets, extended-release capsules, osmotic systems, and multiparticulate formulations.

Issue	US 6,210,705	Oral methylphenidate patent
Delivery route	Topical transdermal or transmucosal	Oral
Main technical focus	Adhesive matrix, flux, wear period, zero-order delivery	Release rate, coating, beads, osmotic delivery, food effect
Key chemical limitation	Acid-functional monomer content	Salt form, particle size, polymer coating, release profile
Bioequivalence risks	Adhesion, skin permeation, residual drug, pharmacokinetics	Dissolution, food effect, pharmacokinetics
Biosimilar analysis	Not applicable	Not applicable
Current status of US 6,210,705	Expired	Depends on the specific oral product and patents

A generic oral methylphenidate product does not practice the transdermal claims merely because it contains the same active ingredient.

What geographic rights does US 6,210,705 provide?

US 6,210,705 provides rights only in the United States. It does not directly restrict products made, sold, or used outside the United States.

Foreign counterparts, if granted, would require separate analysis by country. Relevant differences may include:

National phase filing status.
Local patent term.
Claim amendments.
Opposition or revocation proceedings.
Supplementary protection certificates.
Local regulatory approval.
Separate patent expiration dates.

The US expiration date cannot be assumed to establish the status of corresponding European, Canadian, Japanese, or other foreign rights.

Key Takeaways

US 6,210,705 covers methylphenidate in a flexible, finite topical delivery system.
The core claim requires at least 10-hour delivery, substantially zero-order kinetics, and no more than about 5 wt% acid-functional monomers.
Narrower claims cover methylphenidate base, d-threo-methylphenidate, specific drug loading, adhesive classes, 12-20-hour delivery, and a 1 wt% acid-functional monomer limit.
Claims 18 through 26 cover 24-hour total delivery and specified daily dose ranges.
The patent expired on December 22, 2018.
It no longer creates a live US patent barrier to generic methylphenidate transdermal entry.
Current risk must be assessed against later patents, regulatory requirements, manufacturing know-how, and product-specific Orange Book listings.
Biosimilar risk is irrelevant because methylphenidate is a synthetic small molecule, not a biologic.
The patent remains important as a technical reference for adhesive selection, drug loading, delivery kinetics, and design-around strategy.

FAQs About US Patent 6,210,705

Does US 6,210,705 cover Daytrana?

Yes. The patent’s claimed technology corresponds to the methylphenidate transdermal product architecture used by Daytrana, although product coverage must be evaluated against the claims and the complete patent listing for the applicable NDA.

Can a generic methylphenidate patch launch despite US 6,210,705?

Yes. The patent expired in 2018. A current applicant must address any later patents and satisfy FDA approval requirements, but this patent alone does not block launch.

Does the patent cover methylphenidate tablets or capsules?

No. The claims require a flexible, finite topical delivery system applied to skin or mucosa. Oral methylphenidate products fall outside those limitations.

Is the d-threo enantiomer required in every claim?

No. Claim 5 expressly addresses a composition substantially comprising d-threo-methylphenidate, but the independent claims are not all limited to that enantiomer.

Can a patch avoid the patent by using more than 5 wt% acid-functional monomers?

That formulation may avoid literal infringement of claims containing the no-more-than-5-wt% limitation, subject to the full claim language, prosecution history, and any separately applicable patent claims. The patent expired, so this question is now primarily relevant to historical infringement and technical design analysis.

References

Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/scripts/cder/ob/

Food and Drug Administration. (2006). Daytrana (methylphenidate transdermal system) prescribing information. U.S. Department of Health and Human Services.

United States Patent and Trademark Office. (2001). Methylphenidate transdermal delivery system, U.S. Patent No. 6,210,705. U.S. Department of Commerce.

United States Patent and Trademark Office. (2024). Patent term adjustment and patent term expiration guidance. U.S. Department of Commerce.

U.S. Congress. (2011). 35 U.S.C. § 154: Contents and term of patent; provisional rights. Cornell Law School, Legal Information Institute. https://www.law.cornell.edu/uscode/text/35/154

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	014062	⤷ Start Trial
Austria	260652	⤷ Start Trial
Australia	1824999	⤷ Start Trial
Australia	752027	⤷ Start Trial
Brazil	9814282	⤷ Start Trial
Canada	2315237	⤷ Start Trial
China	101120934	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,210,705

Summary for Patent: 6,210,705